A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT06215755 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by Sponsor due to lack of risk-benefit data.

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: VRG50635

Sponsor

Verge Genomics